Live
- Risk of Middle East escalation
- 50 families quit YSRCP, join TDP
- Nara Bhuvaneshwari to File Nomination Papers on Behalf of TDP Chief Chandrababu in Kuppam
- Tamil Nadu BJP Chief Announces End Of Dravidian Politics, Foresees BJP Surge
- YS Jagan's Memanta Siddham Bus Yatra begins in Rajapuram, to enter Kakinada by evening
- Not just promises, look for capacity to deliver them
- Sujana Chowdary files papers for Vijayawada West
- Unlocking the Potential of FASTag: Enhancing Parking Solutions with RFID Technology
- TDP-BJP-JSP leaders file Lokesh’s nomination
- Hyderabad: Opposition indulging in divisive politics says BJP MP Laxman
Mylan completes acquisition of Jai Pharma
Mylan Laboratories Limited, a subsidiary of Nasdaq-listed Mylan NV, on Friday said it successfully completed the acquisition of certain women’s healthcare businesses - known as Jai Pharma - which were hived off from Famy Care Limited. However, it did not disclose financial details of the acquisition.
Hyderabad: Mylan Laboratories Limited, a subsidiary of Nasdaq-listed Mylan NV, on Friday said it successfully completed the acquisition of certain women’s healthcare businesses - known as Jai Pharma - which were hived off from Famy Care Limited. However, it did not disclose financial details of the acquisition.
The transaction brings Mylan a broad women’s care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan's global commercial footprint and supply chain infrastructure, will create a leading women’s healthcare franchise.
"The completion of this transaction is an important milestone as we continue to grow our global women’s healthcare franchise, and take another step in our mission to provide the world’s 7 billion people access to high quality medicine,” said Mylan CEO Heather Bresch. In addition to strengthening our women’s healthcare offering in North America, we will continue to leverage our powerful commercial platform in Europe, now enhanced through our recent Abbott deal, to serve this important therapeutic area, he added.
